IDegLira plus insulin aspart delivers superior short-term glycemic control in overweight T2DM patients
Background
Type 2 Diabetes Mellitus (T2DM) is a progressive metabolic disorder characterized by insulin resistance and impaired β-cell function, often leading to severe hyperglycemia. Traditional intensive insulin therapy, while effective, can be associated with high insulin requirements, increased risk of hypoglycemia, and slower attainment of glycemic targets. The combination of basal insulin with a GLP-1 receptor agonist like liraglutide (as in IDegLira) offers a synergistic approach, potentially improving glycemic stability, reducing insulin dose, and enhancing β-cell function beyond what insulin monotherapy can achieve, addressing critical gaps in rapid glycemic stabilization.
Study Design
This randomized study compared 7-day intensive therapy in severely hyperglycemic overweight or obese T2DM patients. One group received IDegLira (insulin degludec/liraglutide) plus insulin aspart, while the control group received insulin glargine plus insulin aspart. The primary endpoint was the proportion of patients achieving high-quality glycemic control, defined as time in range (TIR) > 70%, coefficient of variation (CV) < 36%, and no hypoglycemia. Secondary endpoints included continuous glucose monitoring (CGM) metrics, insulin requirements, and indices of insulin resistance and β-cell function.
Results
Compared to the insulin glargine group, the IDegLira group demonstrated significantly higher TIR (84.03% vs. 74.67%, P=0.007) and lower time above range (TBR) (P=0.005). Glycemic variability indices, including mean glucose (MG) (8.26 vs. 9.74 mmol/L), were also significantly improved across all measures (all P≤0.003). The IDegLira group required less insulin daily (37.95 vs. 41.59 U/d, P=0.03) and achieved glycemic targets significantly faster (3.1 vs. 5.0 days, P<0.001).
Key Findings
- IDegLira group achieved higher
TIR(84.03%) vs. insulin glargine (74.67%, P=0.007). - High-quality glycemic control rate was 65.1% with IDegLira vs. 36.5% with insulin glargine (P=0.001).
- IDegLira reduced mean glucose (
MG) to 8.26 mmol/L vs. 9.74 mmol/L with insulin glargine (P≤0.003). - Patients on IDegLira required less insulin daily (37.95 U/d vs. 41.59 U/d, P=0.03).
- Glycemic targets were reached faster with IDegLira (3.1 days vs. 5.0 days, P<0.001).
Why It Matters
IDegLira combined with insulin aspart offers a superior short-term intensive therapy strategy for overweight or obese T2DM patients with severe hyperglycemia. This approach could significantly accelerate the attainment of high-quality glycemic control, reduce the overall insulin burden, and improve metabolic parameters like insulin resistance and β-cell function more effectively than basal insulin alone. For clinicians, this suggests a more efficient and potentially safer initial protocol for stabilizing blood glucose, leading to faster patient improvement and potentially better long-term outcomes by establishing tighter control earlier. The reduced insulin requirement is a notable benefit for patient adherence and comfort.
ideglira
liraglutide
insulin-degludec
insulin-glargine
type-2-diabetes
glycemic-control